Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Present Data at Upcoming Medical Meetings

Presenting Preclinical Data at 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain Upcoming Presentation on GBA-PD program at First International Symposium...
September 06, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference

BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
August 08, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
August 04, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference

BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
June 02, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
May 18, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
May 16, 2022 16:05 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. ...
May 11, 2022 09:30 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

BETHESDA, Md., May 11, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
May 06, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress

BETHESDA, Md., May 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company applying its proprietary computational discovery platform...
April 26, 2022 17:19 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with...